BE636492A - - Google Patents
Info
- Publication number
- BE636492A BE636492A BE636492DA BE636492A BE 636492 A BE636492 A BE 636492A BE 636492D A BE636492D A BE 636492DA BE 636492 A BE636492 A BE 636492A
- Authority
- BE
- Belgium
- Prior art keywords
- vaccine
- virus
- foot
- type
- mouth disease
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 claims description 87
- 241000700605 Viruses Species 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 35
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 29
- 230000002238 attenuated effect Effects 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 101710140501 Sulfate adenylyltransferase subunit 2 1 Proteins 0.000 claims description 9
- 229940031348 multivalent vaccine Drugs 0.000 claims description 8
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 6
- -1 barium cations Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 101150049479 CCNC gene Proteins 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229960000633 dextran sulfate Drugs 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 229960002086 dextran Drugs 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 241000710211 Foot-and-mouth disease virus - type SAT 1 Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 238000011001 backwashing Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE636492A true BE636492A (OSRAM) |
Family
ID=202493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE636492D BE636492A (OSRAM) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE636492A (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2128160A2 (en) * | 1971-03-09 | 1972-10-20 | Pasteur Institut | Pathological process inhibitor prodn - anti-leukaemic agent |
-
0
- BE BE636492D patent/BE636492A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2128160A2 (en) * | 1971-03-09 | 1972-10-20 | Pasteur Institut | Pathological process inhibitor prodn - anti-leukaemic agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2723740A1 (fr) | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications | |
| DE69110082T2 (de) | Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae. | |
| WO2010116096A1 (fr) | Procede de purification du virus rabique | |
| US10294460B2 (en) | Process for the purification of poliovirus from cell cultures | |
| DE2851928C2 (OSRAM) | ||
| WO2015059714A1 (en) | Emergency mode in a hybrid vehicle | |
| US20220298493A1 (en) | Inactivation process for viruses | |
| BE1001964A4 (fr) | Anticorps monoclonal humain et hybridome le produisant. | |
| JP2019514963A (ja) | 免疫抑制化合物および組成物としてのグリコーゲンおよびフィトグリコーゲンナノ粒子ならびにそれらの使用方法 | |
| US4206014A (en) | Process for removing detergents from virus-antigen suspensions | |
| KR101617464B1 (ko) | Ｉｐｖ―ｄｐｔ 백신 | |
| DE2833545A1 (de) | Hochmolekulare meningokokken- gruppe c-vaccine und verfahren zu ihrer herstellung | |
| BE636492A (OSRAM) | ||
| FR2483779A1 (fr) | Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins | |
| FR2570081A1 (fr) | Polysaccharides membranaires utiles notamment comme medicament et procede pour leur preparation | |
| RU2648143C2 (ru) | Способы выделения вирусоподобных частиц | |
| Åkerblom et al. | Formation and characterization of FeLV ISCOMs | |
| CN117756958B (zh) | 一种制备肺炎链球菌荚膜多糖或其降解多糖的方法 | |
| RU2420314C1 (ru) | Способ получения живой культуральной вакцины против вируса гриппа | |
| Wang et al. | Efficient purification of cell culture-derived classical swine fever virus by ultrafiltration and size-exclusion chromatography | |
| CN105396128A (zh) | 一种纯化脊髓灰质炎病毒液的方法 | |
| CN113975412A (zh) | 一种评价轮状病毒疫苗有效性的方法 | |
| CN106434570B (zh) | 一种狂犬病病毒裂解液及其应用 | |
| RU2839456C1 (ru) | Вакцина против ящура генотипа SAT-1/X культуральная цельновирионная инактивированная эмульсионная | |
| RU2765951C1 (ru) | Способ очистки гиалуроната от эндотоксинов |